扎鲁替尼

Description

Zanubrutinib · CAS 1691249-45-2 · C27H29N5O3. UNII AG9MHG098Z.

Identification

CAS Registry Number	1691249-45-2
PubChem CID	135565884
Molecular formula	C27H29N5O3
IUPAC name	(7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide
UNII (FDA)	AG9MHG098Z

Computed Descriptors

Molecular Weight	471.5
XLogP3	3.5
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	6
Exact Mass	471.22703980
Monoisotopic Mass	471.22703980
Topological Polar Surface Area	102
Heavy Atom Count	35
Formal Charge	0

Physical description & handling notes

• Zanubrutinib is an immunomodulating agent that decreases the survival of malignant B cells. It inhibits BTK by binding to its active site. It works to inhibit the proliferation and survival of malignant B cells to reduce the tumour size in mantle cell lymphoma.

GHS Hazard Classification

Reported hazard statements	H360 (100%)

Documented Uses

• Zanubrutinib is indicated for the treatment of: - Mantle cell lymphoma (MCL) in adults who have received at least one prior therapy. - Waldenström’s macroglobulinemia in adults. - Relapsed or refractory marginal zone lymphoma (MZL) in adults who have received at least one anti-CD20-based regimen. - Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults. - Refractory or relapsed follicular lymphoma, in combination with [obinutuzumab], in adults who have received at least two prior systemic
• Zanubrutinib is an oral inhibitor of Bruton’s tyrosine kinase that is used in the therapy of refractory mantle cell lymphoma. Zanubrutinib has been associated with a low rate of serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent acute liver injury although it may pose a risk for reactivation of hepatitis B in susceptible patients.
• Breast Feeding; Lactation; Antineoplastic Agents; Enzyme Inhibitors; Hematologic Agents; Protein Kinase Inhibitors
• Zanubrutinib is approved to be used alone or with other drugs to treat adults with:
• • Chronic lymphocytic leukemia or small lymphocytic lymphoma.
• • Follicular lymphoma in patients who have received at least two types of systemic therapy but it did not work or is no longer working. It is used with obinutuzumab.¹

Synonyms

Zanubrutinib; 1691249-45-2; Brukinsa; BGB-3111; AG9MHG098Z; DTXSID701026208; zanubrutinibum; BTK-InhB; RefChem:57294; DTXCID701510461; Zanubrutinib [INN]; Zanubrutinib [USAN]; BGB3111; UNII-AG9MHG098Z; 1691249-45-2 (S-isomer); Zanubrutinib (BGB-3111)

Frequently Asked Questions

What are the CAS number and molecular formula of Zanubrutinib?

CAS 1691249-45-2; molecular formula C27H29N5O3; molecular weight — g/mol.

What other names is Zanubrutinib known by?

Zanubrutinib, 1691249-45-2, Brukinsa, BGB-3111, AG9MHG098Z, DTXSID701026208.

Is Zanubrutinib classified as hazardous?

Hazard statements reported: H360.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.